Original Article
Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults
N Engl J Med 2010; 362:800-811March 4, 2010
- Abstract
Background
Fasting glucose is the standard measure used to diagnose diabetes in the United States. Recently, glycated hemoglobin was also recommended for this purpose.
Methods
We compared the prognostic value of glycated hemoglobin and fasting glucose for identifying adults at risk for diabetes or cardiovascular disease. We measured glycated hemoglobin in whole-blood samples from 11,092 black or white adults who did not have a history of diabetes or cardiovascular disease and who attended the second visit (occurring in the 1990–1992 period) of the Atherosclerosis Risk in Communities (ARIC) study.
Results
The glycated hemoglobin value at baseline was associated with newly diagnosed diabetes and cardiovascular outcomes. For glycated hemoglobin values of less than 5.0%, 5.0 to less than 5.5%, 5.5 to less than 6.0%, 6.0 to less than 6.5%, and 6.5% or greater, the multivariable-adjusted hazard ratios (with 95% confidence intervals) for diagnosed diabetes were 0.52 (0.40 to 0.69), 1.00 (reference), 1.86 (1.67 to 2.08), 4.48 (3.92 to 5.13), and 16.47 (14.22 to 19.08), respectively. For coronary heart disease, the hazard ratios were 0.96 (0.74 to 1.24), 1.00 (reference), 1.23 (1.07 to 1.41), 1.78 (1.48 to 2.15), and 1.95 (1.53 to 2.48), respectively. The hazard ratios for stroke were similar. In contrast, glycated hemoglobin and death from any cause were found to have a J-shaped association curve. All these associations remained significant after adjustment for the baseline fasting glucose level. The association between the fasting glucose levels and the risk of cardiovascular disease or death from any cause was not significant in models with adjustment for all covariates as well as glycated hemoglobin. For coronary heart disease, measures of risk discrimination showed significant improvement when glycated hemoglobin was added to models including fasting glucose.
Conclusions
In this community-based population of nondiabetic adults, glycated hemoglobin was similarly associated with a risk of diabetes and more strongly associated with risks of cardiovascular disease and death from any cause as compared with fasting glucose. These data add to the evidence supporting the use of glycated hemoglobin as a diagnostic test for diabetes.
Media in This Article
Figure 1
The Incidence Rate of Self-Reported Diagnosed Diabetes in the Study Population, According to the Baseline Glycated Hemoglobin Category.Figure 2
Adjusted Hazard Ratios for Self-Reported Diagnosed Diabetes and Coronary Heart Disease, Ischemic Stroke, and Death from Any Cause, According to the Baseline Glycated Hemoglobin Value.Article Activity
- Article
Fasting glucose is the standard measure used for the diagnosis of diabetes in the United States.1,2 Historically, glycated hemoglobin has been recommended only for the determination of glucose control among persons who have already received the diagnosis of diabetes. New clinical practice recommendations from the American Diabetes Association advocate the use of glycated hemoglobin in the diagnosis of diabetes, largely on the basis of the established association between glycated hemoglobin and microvascular disease.3 Compared with fasting glucose, glycated hemoglobin has several advantages as a diagnostic test: it has higher repeatability,4-6 can be assessed in the nonfasting state, and is the preferred test for monitoring glucose control.1 Long-term prognostic data are also useful for informing diagnostic cutoff points for asymptomatic conditions, and there is evidence that elevated glycated hemoglobin values may be a risk factor for macrovascular disease.
This study was designed to characterize and compare the relationships between values of glycated hemoglobin and fasting glucose and the risk of diabetes, coronary heart disease, ischemic stroke, and death from any cause in a large community-based cohort of middle-aged adults who did not have a history of diabetes. We also investigated whether the association of glycated hemoglobin with newly diagnosed cardiovascular disease could be explained by the intervening development of diabetes. We hypothesized that glycated hemoglobin would be superior to fasting glucose as an indicator of risk for the development of diabetes and cardiovascular disease and for death, with possible differences on the basis of race or ethnic group. Blacks who have diabetes are well known to have higher glycated hemoglobin values than their white counterparts; the same disparity holds among nondiabetic adults.7-10 However, the clinical implications of these disparities are unknown, and few data exist on glycated hemoglobin and outcomes among blacks.
Methods
Study Population
The Atherosclerosis Risk in Communities (ARIC) study is a community-based prospective cohort study of 15,792 middle-aged adults from four U.S. communities. The first examination of participants (visit 1) took place during the 1987–1989 period, with three follow-up visits taking place, each approximately every 3 years.11,12 Visit 2 (during 1990–1992), attended by 14,348 participants, was the only visit for which stored whole-blood samples were available for measurement of glycated hemoglobin; this was the baseline visit in the present study. We excluded participants who identified themselves as other than white or black, as well as those who had self-reported diabetes or use of diabetes medication (as recorded during visit 1 or visit 2), or a history of cardiovascular disease (as recorded during visit 1 or visit 2) or a validated cardiovascular event between visit 1 and visit 2 or who were in a nonfasting state or had missing data. Our final sample size was 11,092 persons. Institutional review boards at each clinical site approved the study protocol, and written informed consent was obtained from all participants.
Measurement of Glycated Hemoglobin
We thawed and assayed frozen whole-blood samples collected at ARIC visit 2 for the measurement of glycated hemoglobin using high-performance liquid chromatography (with the use of the Tosoh A1c 2.2 Plus Glycohemoglobin Analyzer method in 2003–2004 and the Tosoh G7 method in 2007–2008, Tosoh Corp). (Both instruments were standardized to the Diabetes Control and Complications Trial assay.)
Assessment of Diabetes
The serum glucose level was measured by means of the hexokinase method. We used two definitions of newly identified diabetes: a visit-based definition and an interview-based definition. Visit-based diabetes was defined according to a standard time-to-diabetes definition based on glucose measurements, a self-reported diagnosis of diabetes, or medication use for a maximum of 6 years of follow-up.13 Interview-based diabetes was defined on the basis of a self-reported diabetes diagnosis or diabetes medication use during the ARIC visits and subsequent annual telephone calls for a maximum of 15 years of follow-up.
Other Variables of Interest
Plasma lipid level,14-17 body-mass index (BMI), waist-to-hip ratio,18 and blood pressure19 were measured according to the published methods. Hypertension was defined as the average of two blood-pressure readings at the visit (with systolic blood pressure having a cutoff point of 140 mm Hg or higher and diastolic blood pressure having a cutoff point of 90 mm Hg or higher) or the use of hypertension medication. Participants reported their education level, alcohol use, and smoking status. The level of physical activity was assessed with the use of Baecke's questionnaire at ARIC visit 1.20
Surveillance for Newly Diagnosed Coronary Heart Disease, Stroke, and Death from Any Cause
The ascertainment of deaths and classification of cardiovascular events are detailed elsewhere.21,22 Briefly, potential cardiovascular hospitalizations were reported annually by participants and also identified through community-wide hospital surveillance. Trained personnel abstracted hospital records related to possible cardiovascular events.22 Silent myocardial infarctions, as detected by means of electrocardiography during the visits, were identified and recorded. We defined newly diagnosed coronary heart disease as a definite or probable myocardial infarction, a death from coronary heart disease, a cardiac procedure, or electrocardiographic evidence of a silent myocardial infarction. We also examined definite or probable ischemic stroke. Adjudicated follow-up data for cardiovascular events were available up to January 1, 2006.
Statistical Analysis
Baseline characteristics of the study population (from ARIC visit 2) were calculated both overall and according to categories of glycated hemoglobin values (<5.0%, 5.0 to <5.5%, 5.5 to <6.0%, 6.0 to <6.5%, and ≥6.5%). Adjusted hazard ratios and corresponding 95% confidence intervals were estimated with the use of Cox proportional-hazards models. The three core models were as follows: Model 1 was adjusted for age, sex, and race. Model 2 was adjusted for age, sex, race, low-density and high-density cholesterol levels, triglyceride level, BMI, waist-to-hip ratio, hypertension, family history of diabetes, education level, alcohol use, physical activity, and smoking status. We evaluated models 1 and 2 with regard to either the glycated hemoglobin categories (called models 1a and 2a) or standard fasting glucose categories (<100, 100 to <126, and ≥126 mg per deciliter [5.6, 5.6 to <7.0, and ≥7.0 mmol per liter, respectively]) (called models 1b and 2b). Finally, model 3 was adjusted for all the variables in model 2 plus either the baseline fasting glucose level (model 3a) or the baseline glycated hemoglobin value (model 3b).
The glycated hemoglobin category of 5.0 to less than 5.5% had the largest number of participants (4950) and was used as the reference category. To assess the continuous associations between the glycated hemoglobin value and clinical outcomes in the models, we generated piecewise linear splines with knots corresponding to the glycated hemoglobin cutoff points used in this study; we also implemented restricted cubic splines to obtain a smoother fit to the data. Model discrimination was assessed with the use of Harrell's C statistic.23
We tested for interactions with race and sex. To investigate whether a diagnosis of diabetes made before a cardiovascular event or death could explain potential associations with glycated hemoglobin, we conducted analyses in which cases of diagnosed diabetes occurring before the event of interest were censored. We also conducted analyses examining the association of each outcome with the baseline glycated hemoglobin value after excluding persons with a fasting glucose level of 126 mg per deciliter or higher at either ARIC visit 1 or 2. To assess whether glycated hemoglobin was associated with a risk of the outcomes across categories of fasting glucose at baseline, we conducted analyses of combined categories of glycated hemoglobin and fasting glucose. To evaluate the overall improvement in risk classification for the addition of glycated hemoglobin to fully adjusted models including fasting glucose, we calculated the net-reclassification-improvement statistic and the integrated-discrimination-improvement statistic.24
All reported P values are two-sided. They are not adjusted for multiple comparisons.
Results
Baseline characteristics of the study population, both overall and according to the glycated hemoglobin category, are shown in Table 1Table 1
Selected Characteristics of the Study Participants, According to the Glycated Hemoglobin Value at Baseline.. Glycated hemoglobin and fasting glucose levels at baseline were highly correlated (r=0.73). Participants with elevated glycated hemoglobin levels were more likely to be black than white, and to have fewer years of education, and to have an adverse lipid profile and a higher BMI and were less likely to be current drinkers than to have formerly or never used alcohol. As documented in previous studies, in our nondiabetic population, blacks had significantly higher mean glycated hemoglobin values (5.8%) than whites (5.4%) (P<0.001).The median follow-up time was approximately 14 years. More than 80% of the participants attended each clinic visit, and retention of ARIC participants during the follow-up period was high (>90%). During the first 6 years of follow-up, 620 participants were identified as having diabetes, according to the visit-based diabetes definition. During the full 15 years of follow-up, 2251 participants reported a diagnosis of diabetes or use of diabetes medication (the interview-based definition of diabetes), there were 1198 validated cases of coronary heart disease and 358 validated cases of ischemic stroke, and 1447 participants died.
The crude cumulative 15-year incidence (calculated as the incidence proportion) of self-reported diabetes was 20%. (See the Supplementary Appendix, available with the full text of this article at NEJM.org, for a discussion of self-reported diabetes vs. verified diabetes.) The cumulative incidence of diagnosed diabetes was 6%, 12%, 21%, 44%, and 79% among participants with a glycated hemoglobin value of less than 5.0%, 5.0 to less than 5.5%, 5.5 to less than 6.0%, 6.0 to less than 6.5%, and 6.5% or higher, respectively. The incidence rates (per 1000 person-years) are shown according to the category of glycated hemoglobin in Figure 1Figure 1
The Incidence Rate of Self-Reported Diagnosed Diabetes in the Study Population, According to the Baseline Glycated Hemoglobin Category.. The adjusted hazard ratios (and 95% confidence intervals) of the 6-year risk of visit-based diabetes and 15-year risk of the other outcomes are shown in Table 2Table 2
Adjusted Hazard Ratios for Selected Clinical Outcomes in the Study Population during the 15-Year Study Period, According to the Glycated Hemoglobin Category at Baseline and the Model. according to the category of glycated hemoglobin. A baseline glycated hemoglobin value of less than 5.0%, as compared with a value of 5.0 to less than 5.5%, was associated with approximately half the risk of visit-based or diagnosed diabetes (hazard ratios for each outcome in models 1 and 2, approximately 0.50). Additional adjustment for the fasting glucose level (in model 3a) attenuated this association, but the glycated hemoglobin category remained strongly associated with diagnosed diabetes. We also observed significant trends of an increasing risk of coronary heart disease, ischemic stroke, and death from any cause with higher levels of baseline glycated hemoglobin. These associations persisted even after adjustment for fasting glucose (model 3a).Figure 2Figure 2
Adjusted Hazard Ratios for Self-Reported Diagnosed Diabetes and Coronary Heart Disease, Ischemic Stroke, and Death from Any Cause, According to the Baseline Glycated Hemoglobin Value. depicts the adjusted hazard ratios for diagnosed diabetes, coronary heart disease, stroke, and death from any cause and the baseline glycated hemoglobin category — per each absolute increase of 1 percentage point in the glycated hemoglobin value. There was no evidence of a threshold value of glycated hemoglobin for diagnosed diabetes, but there was evidence for a possible threshold for the risk of coronary heart disease. There was no significant association between the glycated hemoglobin value and the risk of coronary heart disease at glycated hemoglobin values of less than 5.0%, but as compared with that category, glycated hemoglobin values of 5.5% or higher were associated with a hazard ratio for coronary heart disease of 1.38 (95% confidence interval [CI], 1.22 to 1.56). For death from any cause, we observed a J-shaped association. Participants with glycated hemoglobin values in the lowest category (<5.0%) had a significantly higher risk of death from any cause as compared with those with glycated hemoglobin levels of 5.0 to less than 5.5% (Table 2 and Figure 2). In post hoc analyses, the J-shaped association persisted after the exclusion of participants with anemia, adjustment for hematocrit level and mean corpuscular volume, and the exclusion of deaths that occurred during the first 3 years of follow-up (data not shown). In analyses censoring data for persons who received a diagnosis of diabetes during the follow-up period, the associations remained significant between glycated hemoglobin and coronary heart disease, stroke, and death from any cause.The fasting glucose categories were associated with the risks of outcomes in the minimally adjusted models, but these associations were attenuated after adjustment for other risk factors (Table 3Table 3
Adjusted Hazard Ratios for Selected Clinical Outcomes in the Study Population during the 15-Year Study Period, According to the Fasting Glucose Category at Baseline and the Model.). As compared with a baseline fasting glucose level of less than 100 mg per deciliter, a level of 100 to less than 126 mg per deciliter was associated with diagnosed diabetes (hazard ratio, 2.31; 95% CI, 2.06 to 2.59) but not with coronary heart disease (hazard ratio, 1.03; 95% CI, 0.91 to 1.18), ischemic stroke (hazard ratio, 0.97; 95% CI, 0.76 to 1.23), and death from any cause (hazard ratio, 1.07; 95% CI, 0.96 to 1.21) after adjustment for covariates (model 2b) (Table 3), whereas undiagnosed diabetes (defined as a fasting glucose level of 126 mg per deciliter or higher at baseline) was significantly, independently associated with the development of coronary heart disease (hazard ratio, 1.29; 95% CI, 1.04 to 1.61), ischemic stroke (hazard ratio, 1.89; 95% CI, 1.33 to 2.69), and death from any cause (hazard ratio, 1.31; 95% CI, 1.07 to 1.61). After additional adjustment for glycated hemoglobin in model 3b, there was no significant association between fasting glucose category and the risk of coronary heart disease, ischemic stroke, or death from any cause. Among the 10,069 participants with a fasting glucose level of less than 126 mg per deciliter at visit 1 and visit 2, the glycated hemoglobin category was similarly associated, in model 3b as compared with models 1b and 2b, with diagnosed diabetes, coronary heart disease, stroke, and death from any cause (Table 2 in the Supplementary Appendix).We also assessed the associations of three categories of glycated hemoglobin (<6.0%, 6.0 to <6.5%, and ≥6.5%) with the risks of outcomes among participants stratified according to the fasting glucose category (<100, 100 to <126, and ≥126 mg per deciliter) (Table 3 in the Supplementary Appendix). The glycated hemoglobin categories of 6.0 to less than 6.5% and 6.5% or higher were significantly associated with all outcomes within each fasting glucose category, with the association increasing with higher glycated hemoglobin categories. In contrast, if the glycated hemoglobin value was less than 6.0%, fasting glucose was not significantly associated with coronary heart disease, ischemic stroke, or death from any cause.
There was no significant interaction between sex and glycated hemoglobin category for any of the clinical outcomes (P>0.20 for all interactions). There was also no significant interaction between race and glycated hemoglobin value regarding the risk of coronary heart disease, ischemic stroke, or death from any cause (P>0.80 for all interactions). However, race did appear to modify the association between the glycated hemoglobin value and the risk of diagnosed diabetes during 15 years of follow-up (P=0.007 for interaction), but there was no interaction between race and the association between glycated hemoglobin value and the 6-year risk of visit-based diabetes (P=0.81 for interaction). As compared with whites, blacks had lower adjusted hazard ratios for reporting a diagnosis of diabetes during the 15 years of follow-up, within each category of glycated hemoglobin. A similar interaction was also observed between race and fasting glucose level regarding the risk of self-reported diabetes (P=0.01 for interaction).
The net-reclassification-improvement and integrated-discrimination-improvement statistics for diagnosed diabetes and coronary heart disease were significantly improved with the addition of glycated hemoglobin (modeled continuously) to the model of fasting glucose (as a continuous variable) and other covariates (see the Supplementary Appendix).
Discussion
Among the people in the United States who do not have a diagnosis of diabetes, over 2.4 million have a glycated hemoglobin value higher than 6.5% and 7 million have a value higher than 6.0%.7 Our findings show that people with a glycated hemoglobin value of 6.0% or higher are at high risk for the development of diabetes, even after adjustment for other risk factors and independently of baseline fasting glucose levels. We also observed that glycated hemoglobin is a marker of cardiovascular risk. In this nondiabetic population, glycated hemoglobin remained associated with cardiovascular disease and death even after we accounted for baseline fasting glucose levels; in contrast, fasting glucose was not significantly associated after adjustment for the glycated hemoglobin value. We also demonstrated improved risk reclassification for coronary heart disease with the inclusion of glycated hemoglobin in fully adjusted models, suggesting that glycated hemoglobin may be superior to fasting glucose for characterizing long-term risk.
Glycated hemoglobin values reflect the 2-to-3-month average endogenous exposure to glucose, including postprandial spikes in the blood glucose level, and have low intraindividual variability, particularly in persons without diabetes.4,25 These characteristics may contribute to the superiority of glycated hemoglobin over fasting glucose for long-term macrovascular risk stratification.
Recommendations for the diagnosis of diabetes are based on the relations of fasting glucose and glycated hemoglobin with microvascular disease, typically retinopathy.1,3 Nonetheless, cardiovascular disease is the leading cause of illness, death, and hospitalization in persons with diabetes.26,27 Our data suggest that glycated hemoglobin values in the normal range can identify persons at increased risk for coronary heart disease, stroke, and death before the diagnosis of diabetes, indicating that glycated hemoglobin is a useful marker of cardiovascular risk and death from any cause. The J-shaped relation between the glycated hemoglobin value and the risk of death from any cause suggests that further exploration of the health risks associated with the low-normal glycemic state and possible nonglycemic determinants of glycated hemoglobin is warranted.
As in the present study, the literature has documented an increase in cardiovascular risk with increases in glycated hemoglobin values within the nondiabetic range.28-36 We have previously shown (using a case–cohort design) associations of glycated hemoglobin with coronary heart disease and stroke in a subgroup of the ARIC population with low fasting glucose levels (at two time points) and low glycated hemoglobin values37 and, separately, among persons with diabetes.38 Nonetheless, recent clinical trials have shown little benefit, and possibly some harm, of lowering the glycated hemoglobin value in patients with diabetes to prevent cardiovascular outcomes.39-43 In contrast, the microvascular benefits of glucose control are well established.44,45 Although the causal role of glucose itself in the development of cardiovascular disease is unclear, our data demonstrate that glycated hemoglobin within the normal range can be a useful marker of cardiovascular risk. Therefore, glycated hemoglobin values exceeding 6.0% may be a clinically useful marker to identify persons at risk for the development of not only diabetes but also cardiovascular disease and death.
Despite significant differences between blacks and whites in glycated hemoglobin values at baseline, race did not modify the associations between glycated hemoglobin value and cardiovascular outcomes and death in this population. We did, however, observe a significant interaction between race and diagnosed diabetes during the 15 years of follow-up (but not for the 6-year visit-based definition), revealing that blacks were significantly less likely than whites to report a diabetes diagnosis, across all categories of glycated hemoglobin. We observed a similar race interaction for baseline fasting glucose level and subsequent diagnosis of diabetes. Thus, higher values of glycated hemoglobin in nondiabetic blacks as compared with nondiabetic whites might be partially explained by delays in diagnosis. Our findings do not support the use of race-specific glycated hemoglobin cutoff points for the identification of persons at risk for diabetes, cardiovascular disease, or death.
Important limitations of this study include the reliance on single glycated hemoglobin and glucose measurements at baseline, a limited number of fasting glucose measurements during the follow-up period, and the lack of validation of self-reported diabetes for the 15-year analyses. Nonetheless, among sensitivity analyses comparing diabetes definitions based on fasting glucose level, medication use, and self-reported information — all available for the first 6 years of the follow-up period — our results were similar (see the Supplementary Appendix). Owing to the observational nature of our investigation, the possibility of residual confounding cannot be completely eliminated. Nonetheless, this effort is one of the largest, community-based studies of glycated hemoglobin involving information about the development of diabetes and validated cardiovascular events during follow-up. Major strengths of this ARIC ancillary study were the use of comprehensive surveillance and adjudication of cardiovascular events and rigorous measurement of risk factors. The large population of blacks was an additional strength, permitting us to conduct robust analyses of possible racial differences in risk.
In this community-based study population of black or white nondiabetic adults, glycated hemoglobin was superior to fasting glucose for assessment of the long-term risk of subsequent cardiovascular disease, especially at values above 6.0%. Such prognostic data may add to the evidence supporting the use of glycated hemoglobin as a diagnostic test for diabetes.
Supported by grants from the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R21 DK080294 and K01 DK076595, to Dr. Selvin; and K24 DK62222, to Dr. Brancati); contracts with the National Heart, Lung, and Blood Institute (N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022); and an NIDDK grant (P60 DK079637, to Dr. Brancati through the Johns Hopkins Diabetes Research and Training Center).
Financial and other disclosures provided by the authors are available with the full text of this article at NEJM.org.
Source Information
From the Department of Epidemiology and the Welch Center for Prevention, Epidemiology, and Clinical Research (E.S., K.M., J.C., F.L.B.), and the Department of Biostatistics (H.Z., J.C.), Johns Hopkins Bloomberg School of Public Health; and the Division of General Internal Medicine, Department of Medicine, Johns Hopkins University (E.S., J.C., F.L.B.) — all in Baltimore; the Department of Laboratory Medicine and Pathology, Medical School (M.W.S.), and the Division of Epidemiology and Community Health (J.P.), University of Minnesota, Minneapolis; and the Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC (L.W.).
Address reprint requests to Dr. Selvin at Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument St., Suite 2-600, Baltimore, MD 21287, or at lselvin@jhsph.edu.
- References
References
1
American Diabetes Association
CrossRef | Web of Science | Medline2
American Diabetes Association
Web of Science | Medline3
American Diabetes Association
CrossRef | Web of Science | Medline4
Selvin E ,Crainiceanu CM ,Brancati FL ,Coresh J . Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007;167:1545-1551
CrossRef | Web of Science | Medline5
Phillipou G ,Phillips PJ . Intraindividual variation of glycohemoglobin: implications for interpretation and analytical goals. Clin Chem 1993;39:2305-2308
Web of Science | Medline6
Rohlfing C ,Wiedmeyer HM ,Little R , et al. Biological variation of glycohemoglobin. Clin Chem 2002;48:1116-1118
Web of Science | Medline7
Selvin E ,Zhu H ,Brancati FL . Elevated A1C in adults without a history of diabetes in the U.S. Diabetes Care 2009;32:828-833
CrossRef | Web of Science | Medline8
Herman WH ,Dungan KM ,Wolffenbuttel BH , et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1689-1694
CrossRef | Web of Science | Medline9
Herman WH ,Ma Y ,Uwaifo G , et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007;30:2453-2457
CrossRef | Web of Science | Medline10
Kirk JK ,D'Agostino RB Jr ,Bell RA , et al. Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care 2006;29:2130-2136
CrossRef | Web of Science | Medline11
The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989;129:687-702
Web of Science | Medline12
Jackson R ,Chambless LE ,Yang K , et al. Differences between respondents and nonrespondents in a multicenter community-based study vary by gender ethnicity. J Clin Epidemiol 1996;49:1441-1446
CrossRef | Web of Science | Medline13
Duncan BB ,Schmidt MI ,Pankow JS , et al. Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 2003;52:1799-1805
CrossRef | Web of Science | Medline14
Siedel J ,Hagele EO ,Ziegenhorn J ,Wahlefeld AW . Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983;29:1075-1080
Web of Science | Medline15
Nagele U ,Hagele EO ,Sauer G , et al. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Clin Biochem 1984;22:165-174
Medline16
Friedewald WT ,Levy RI ,Fredrickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
Web of Science | Medline17
Atherosclerosis Risk in Communities Coordinating Center. Operations manual no. 10: clinical chemistry determinations, version 1.0. Chapel Hill: University of North Carolina School of Public Health, 1987.
18
Idem. Operations manual no. 2: cohort component procedures, version 1.0. Chapel Hill: University of North Carolina School of Public Health, 1987.
19
Idem. Operations manual no. 11: sitting blood pressure, version 1.0. Chapel Hill: University of North Carolina School of Public Health, 1987.
20
Baecke JA ,Burema J ,Frijters JE . A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 1982;36:936-942
Web of Science | Medline21
Rosamond WD ,Folsom AR ,Chambless LE , et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999;30:736-743
CrossRef | Web of Science | Medline22
White AD ,Folsom AR ,Chambless LE , et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol 1996;49:223-233
CrossRef | Web of Science | Medline23
Harrell FE Jr ,Lee KL ,Mark DB . Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387
CrossRef | Web of Science | Medline24
Pencina MJ ,D'Agostino RB ,D'Agostino RB Jr ,Vasan RS . Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172
CrossRef | Web of Science | Medline25
Meigs JB ,Nathan DM ,Cupples LA ,Wilson PW ,Singer DE . Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. J Clin Epidemiol 1996;49:411-417
CrossRef | Web of Science | Medline26
Engelgau MM ,Geiss LS ,Saaddine JB , et al. The evolving diabetes burden in the United States. Ann Intern Med 2004;140:945-950
Web of Science | Medline27
Bertoni AG ,Krop JS ,Anderson GF ,Brancati FL . Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care 2002;25:471-475
CrossRef | Web of Science | Medline28
Stout RL ,Fulks M ,Dolan VF ,Magee ME ,Suarez L . Relationship of hemoglobin A1c to mortality in nonsmoking insurance applicants. J Insur Med 2007;39:174-181
Medline29
Pradhan AD ,Rifai N ,Buring JE ,Ridker PM . Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med 2007;120:720-727
CrossRef | Web of Science | Medline30
de Vegt F ,Dekker JM ,Ruhe HG , et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-931
CrossRef | Web of Science | Medline31
Blake GJ ,Pradhan AD ,Manson JE , et al. Hemoglobin A1c level and future cardiovascular events among women. Arch Intern Med 2004;164:757-761
CrossRef | Web of Science | Medline32
Khaw KT ,Wareham N ,Bingham S ,Luben R ,Welch A ,Day N . Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004;141:413-420
Web of Science | Medline33
Brewer N ,Wright CS ,Travier N , et al. A New Zealand linkage study examining the associations between A1C concentration and mortality. Diabetes Care 2008;31:1144-1149
CrossRef | Web of Science | Medline34
Levitan EB ,Liu S ,Stampfer MJ , et al. HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women. Diabetologia 2008;51:267-275
CrossRef | Web of Science | Medline35
Meigs JB ,Nathan DM ,D'Agostino RB ,Wilson PW . Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25:1845-1850
CrossRef | Web of Science | Medline36
Gerstein HC ,Swedberg K ,Carlsson J , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008;168:1699-1704
CrossRef | Web of Science | Medline37
Selvin E ,Coresh J ,Shahar E ,Zhang L ,Steffes M ,Sharrett AR . Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Lancet Neurol 2005;4:821-826
CrossRef | Web of Science | Medline38
Selvin E ,Coresh J ,Golden SH ,Brancati FL ,Folsom AR ,Steffes MW . Glycemic control and coronary heart disease risk in persons with and without diabetes: the Atherosclerosis Risk in Communities Study. Arch Intern Med 2005;165:1910-1916
CrossRef | Web of Science | Medline39
The Action to Control Cardiovascular Risk in Diabetes Study Group
Full Text | Web of Science | Medline40
Home PD ,Pocock SJ ,Beck-Nielsen H , et al. Rosiglitazone evaluated for cardiovascular outcomes -- an interim analysis. N Engl J Med 2007;357:28-38
Full Text | Web of Science | Medline41
The ADVANCE Collaborative Group
Full Text | Web of Science | Medline42
Nissen SE ,Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471[Erratum, N Engl J Med 2007;357:100.]
Full Text | Web of Science | Medline43
Selvin E ,Bolen S ,Yeh HC , et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008;168:2070-2080
CrossRef | Web of Science | Medline44
The Diabetes Control and Complications Trial Research Group
CrossRef | Web of Science | Medline45
The UK Prospective Diabetes Study (UKPDS) Group
CrossRef | Web of Science | Medline
- Citing Articles (100)
Citing Articles
1
Albert Stuart Reece. (2012) Manifold implications of forgotten hyperglycemia in clinical opiate dependence. Drug and Chemical Toxicology1-12
CrossRef2
A. Vaag, S. Lund. (2012) THERAPY OF ENDOCRINE DISEASE: Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. European Journal of Endocrinology 166:2, 159-170
CrossRef3
Champika Seneviratne, G.W. Dombi, W. Liu, J.A. Dain. (2012) In vitro glycation of human serum albumin by dihydroxyacetone and dihydroxyacetone phosphate. Biochemical and Biophysical Research Communications 417:2, 817-823
CrossRef4
Chris Degeling, Melanie Rock. (2012) Hemoglobin A1c as a Diagnostic Tool: Public Health Implications From an Actor–Network Perspective. American Journal of Public Health 102:1, 99-106
CrossRef5
Jonathan Rubin, Kunihiro Matsushita, Christie M. Ballantyne, Ron Hoogeveen, Josef Coresh, Elizabeth Selvin. (2012) Chronic Hyperglycemia and Subclinical Myocardial Injury. Journal of the American College of Cardiology 59:5, 484-489
CrossRef6
, S. Zoungas, J. Chalmers, T. Ninomiya, Q. Li, M. E. Cooper, S. Colagiuri, G. Fulcher, B. E. Galan, S. Harrap, P. Hamet, S. Heller, S. MacMahon, M. Marre, N. Poulter, F. Travert, A. Patel, B. Neal, M. Woodward. (2011) Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia
CrossRef7
Roma Y. Gianchandani, Sima Saberi, Christina A. Zrull, Preethi V. Patil, Leena Jha, Susan C. Kling-Colson, Kenia G. Gandia, Elizabeth C. DuBois, Cynthia D. Plunkett, Tim W. Bodnar, Rodica Pop-Busui. (2011) Evaluation of Hemoglobin A1c Criteria to Assess Preoperative Diabetes Risk in Cardiac Surgery Patients. Diabetes Technology & Therapeutics 13:12, 1249-1254
CrossRef8
Sara M. Willems, Raluca Mihaescu, Eric J. G. Sijbrands, Cornelia M. Duijn, A. Cecile J. W. Janssens. (2011) A Methodological Perspective on Genetic Risk Prediction Studies in Type 2 Diabetes: Recommendations for Future Research. Current Diabetes Reports 11:6, 511-518
CrossRef9
Achim Peters, Bruce S. McEwen. (2011) Editorial introduction. Physiology & Behavior
CrossRef10
Mihailović Mirjana, Arambašić Jelena, Uskoković Aleksandra, Dinić Svetlana, Grdović Nevena, Marković Jelena, Poznanović Goran, Vidaković Melita. (2011) Alpha-lipoic acid preserves the structural and functional integrity of red blood cells by adjusting the redox disturbance and decreasing O-GlcNAc modifications of antioxidant enzymes and heat shock proteins in diabetic rats. European Journal of Nutrition
CrossRef11
J. I. Reddigan, M. C. Riddell, J. L. Kuk. (2011) The joint association of physical activity and glycaemic control in predicting cardiovascular death and all-cause mortality in the US population. Diabetologia
CrossRef12
Lei Chen, Dianna J. Magliano, Paul Z. Zimmet. (2011) The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nature Reviews Endocrinology
CrossRef13
Line Velling Magnussen, Hanne Mumm, Marianne Andersen, Dorte Glintborg. (2011) Hemoglobin A1c as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndrome. Fertility and Sterility 96:5, 1275-1280
CrossRef14
Hong-Kyu Kim, Chul-Hee Kim, Eun-Hee Kim, Sung-Jin Bae, Joong-Yeol Park. (2011) Usefulness of hemoglobin A1c as a criterion of dysglycemia in the definition of metabolic syndrome in Koreans. Diabetes Research and Clinical Practice
CrossRef15
Janice A Kolberg, Robert W Gerwien, Steve M Watkins, Linda J Wuestehube, Mickey Urdea. (2011) Biomarkers in Type 2 diabetes: improving risk stratification with the PreDx ® Diabetes Risk Score. Expert Review of Molecular Diagnostics 11:8, 775-792
CrossRef16
S. Soulimane, D. Simon, J. E. Shaw, P. Z. Zimmet, S. Vol, D. Vistisen, D. J. Magliano, K. Borch-Johnsen, B. Balkau. (2011) Comparing incident diabetes as defined by fasting plasma glucose or by HbA1c. The AusDiab, Inter99 and DESIR studies. Diabetic Medicine 28:11, 1311-1318
CrossRef17
Philip E. Cryer. (2011) Death during Intensive Glycemic Therapy of Diabetes: Mechanisms and Implications. The American Journal of Medicine 124:11, 993-996
CrossRef18
Vasant Hirani. (2011) Relationship Between Vitamin D and Hyperglycemia in Older People From a Nationally Representative Population Survey. Journal of the American Geriatrics Society 59:10, 1786-1792
CrossRef19
Michael Pfeiffer, Rüdiger Bauer, Peter P. Nawroth. (2011) The new puzzle about the treatment of type 2 diabetes after the ACCORD and Da Qing studies. Langenbeck's Archives of Surgery 396:7, 941-947
CrossRef20
B. Costa, F. Barrio, J.-J. Cabré, J.-L. Piñol, F.-X. Cos, C. Solé, B. Bolibar, C. Castell, J. Lindström, N. Barengo, J. Tuomilehto, . (2011) Shifting from glucose diagnostic criteria to the new HbA1c criteria would have a profound impact on prevalence of diabetes among a high-risk Spanish population. Diabetic Medicine 28:10, 1234-1237
CrossRef21
M.A. Marini, E. Succurro, F. Arturi, M.F. Ruffo, F. Andreozzi, A. Sciacqua, R. Lauro, M.L. Hribal, F. Perticone, G. Sesti. (2011) Comparison of A1C, fasting and 2-h post-load plasma glucose criteria to diagnose diabetes in Italian Caucasians. Nutrition, Metabolism and Cardiovascular Diseases
CrossRef22
William Victor Bobo, Stefania Bonaccorso, Karuna Jayathilake, Herbert Yale Meltzer. (2011) Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder. Psychiatry Research 189:2, 200-207
CrossRef23
B. Kowall, W. Rathmann, R. Landgraf. (2011) Is HbA1c a valid and feasible tool for the diagnosis of diabetes?. Diabetes Research and Clinical Practice 93:3, 314-316
CrossRef24
Arie Shirom, Sharon Toker, Samuel Melamed, Shlomo Berliner, Itzhak Shapira. (2011) Life and Job Satisfaction as Predictors of the Incidence of Diabetes. Applied Psychology: Health and Well-Beingno-no
CrossRef25
Bernd Kowall, Wolfgang Rathmann, Margit Heier, Guido Giani, Annette Peters, Barbara Thorand, Cornelia Huth, Andrea Icks, Christine Meisinger. (2011) Categories of glucose tolerance and continuous glycemic measures and mortality. European Journal of Epidemiology 26:8, 637-645
CrossRef26
R. Pfister, S. J. Sharp, R. Luben, K.-T. Khaw, N. J. Wareham. (2011) No evidence of an increased mortality risk associated with low levels of glycated haemoglobin in a non-diabetic UK population. Diabetologia 54:8, 2025-2032
CrossRef27
Javier Sanz, Valentin Fuster. (2011) The Year in Atherothrombosis. Journal of the American College of Cardiology 58:8, 779-791
CrossRef28
K.J. Joshipura, M.O. Andriankaja, F.B. Hu, C.S. Ritchie. (2011) Relative utility of 1-h Oral Glucose Tolerance Test as a measure of abnormal glucose homeostasis. Diabetes Research and Clinical Practice 93:2, 268-275
CrossRef29
K. G. Kehl, H. M. Findeisen, D. W. Fardo, D. Bruemmer, D. M. Mannino, W. T. Sanderson. (2011) Race-ethnicity as an effect modifier of the association between HbAlc and mortality in U.S. adults without diagnosed diabetes. European Journal of Endocrinology 165:2, 275-281
CrossRef30
Roberto Lorbeer, Klaus Empen, Marcus Dörr, Maria Arndt, Sabine Schipf, Matthias Nauck, Henri Wallaschofski, Stephan B. Felix, Henry Völzke. (2011) Association between glycosylated haemoglobin A1c and endothelial function in an adult non-diabetic population. Atherosclerosis 217:2, 358-363
CrossRef31
Paul S. Fisk, Amanda L. Middaugh, Yeong S. Rhee, Ardith R. Brunt. (2011) Few favorable associations between fruit and vegetable intake and biomarkers for chronic disease risk in American adults. Nutrition Research 31:8, 616-624
CrossRef32
J. Varlotto, L.N. Medford-Davis, A. Recht, J. Flickinger, E. Schaefer, J. Shelkey, M. Lazar, D. Campbell, M. Nikolov, M.M. DeCamp. (2011) Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer. Lung Cancer
CrossRef33
Mark WI Webster. (2011) Clinical practice and implications of recent diabetes trials. Current Opinion in Cardiology 26:4, 288-293
CrossRef34
R. Landgraf, B. Kowall, W. Rathmann. (2011) HbA1c – ein Alleskönner?. Der Diabetologe 7:5, 335-346
CrossRef35
Melinda B Davis, Claire S Duvernoy. (2011) How to stay heart healthy in 2011: considerations for the primary prevention of cardiovascular disease in women. Women's Health 7:4, 433-451
CrossRef36
Xuefeng Liu, Meng Liu, Dennis Tsilimingras, Ernesto L. Schiffrin. (2011) Racial disparities in cardiovascular risk factors among diagnosed hypertensive subjects. Journal of the American Society of Hypertension 5:4, 239-248
CrossRef37
A. Lapolla, A. Mosca, D. Fedele. (2011) The general use of glycated haemoglobin for the diagnosis of diabetes and other categories of glucose intolerance: Still a long way to go. Nutrition, Metabolism and Cardiovascular Diseases 21:7, 467-475
CrossRef38
A. L. Christman, K. Matsushita, R. F. Gottesman, T. Mosley, A. Alonso, J. Coresh, F. Hill-Briggs, A. R. Sharrett, E. Selvin. (2011) Glycated haemoglobin and cognitive decline: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 54:7, 1645-1652
CrossRef39
Manisha Nair, Dorairaj Prabhakaran, K.M. Venkat Narayan, Rashmi Sinha, Ramakrishnan Lakshmy, Niveditha Devasenapathy, Carrie R. Daniel, Ruby Gupta, Preethi S. George, Aleyamma Mathew, Nikhil Tandon, K. Srinath Reddy. (2011) HbA1c values for defining diabetes and impaired fasting glucose in Asian Indians. Primary Care Diabetes 5:2, 95-102
CrossRef40
W. L. Jin, K. Azuma, T. Mita, H. Goto, A. Kanazawa, T. Shimizu, F. Ikeda, Y. Fujitani, T. Hirose, R. Kawamori, H. Watada. (2011) Repetitive hypoglycaemia increases serum adrenaline and induces monocyte adhesion to the endothelium in rat thoracic aorta. Diabetologia 54:7, 1921-1929
CrossRef41
J. B. Echouffo-Tcheugui, M. K. Ali, S. J. Griffin, K. M. V. Narayan. (2011) Screening for Type 2 Diabetes and Dysglycemia. Epidemiologic Reviews 33:1, 63-87
CrossRef42
Jean-Louis Chiasson, Sophie Bernard. (2011) Reducing cardiovascular risk factors in patients with prediabetes. Diabetes Management 1:4, 423-438
CrossRef43
Yoriko Heianza, Shigeko Hara, Yasuji Arase, Kazumi Saito, Kazuya Fujiwara, Hiroshi Tsuji, Satoru Kodama, Shiun Dong Hsieh, Yasumichi Mori, Hitoshi Shimano, Nobuhiro Yamada, Kinori Kosaka, Hirohito Sone. (2011) HbA1c 5·7–6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. The Lancet 378:9786, 147-155
CrossRef44
2011. , 48-52.
CrossRef45
Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas Almdal, Christina Hemmingsen, Jørn Wetterslev, Bianca Hemmingsen. 2011. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. .
CrossRef46
R. Santos-Oliveira, C. Purdy, M. Pereira Silva, A. M. Anjos Carneiro-Leão, M. Machado, T. R. Einarson. (2011) Haemoglobin A1c levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts. Diabetologia 54:6, 1327-1334
CrossRef47
Elena Succurro, Maria Adelaide Marini, Franco Arturi, Alessandro Grembiale, Teresa Vanessa Fiorentino, Francesco Andreozzi, Angela Sciacqua, Renato Lauro, Marta Letizia Hribal, Francesco Perticone, Giorgio Sesti. (2011) Usefulness of Hemoglobin A1c as a Criterion to Define the Metabolic Syndrome in a Cohort of Italian Nondiabetic White Subjects. The American Journal of Cardiology 107:11, 1650-1655
CrossRef48
Sergio Raposeiras-Roubín, Bruno K. Rodiño-Janeiro, Lilian Grigorian-Shamagian, Ana Seoane-Blanco, María Moure-González, Alfonso Varela-Román, Ezequiel Álvarez, José R. González-Juanatey. (2011) Evidence for a role of advanced glycation end products in atrial fibrillation. International Journal of Cardiology
CrossRef49
Isaac Shpirer, Micha J. Rapoport, David Stav, Arnon Elizur. (2011) Normal and elevated HbA1C levels correlate with severity of hypoxemia in patients with obstructive sleep apnea and decrease following CPAP treatment. Sleep and Breathing
CrossRef50
E. Cosson, M. T. Nguyen, E. Hamo-Tchatchouang, I. Banu, S. Chiheb, N. Charnaux, P. Valensi. (2011) What would be the outcome if the American Diabetes Association recommendations of 2010 had been followed in our pratice in 1998-2006?. Diabetic Medicine 28:5, 567-574
CrossRef51
Samir Malkani, John P. Mordes. (2011) Implications of Using Hemoglobin A1C for Diagnosing Diabetes Mellitus. The American Journal of Medicine 124:5, 395-401
CrossRef52
Judith S. Brand, Nicholas J. Wareham, Mitch Dowsett, Elizabeth Folkerd, Yvonne T. van der Schouw, Robert N. Luben, Kay-Tee Khaw. (2011) Associations of endogenous testosterone and SHBG with glycated haemoglobin in middle-aged and older men. Clinical Endocrinology 74:5, 572-578
CrossRef53
J.T. Saltevo, H. Kautiainen, L. Niskanen, H. Oksa, H. Puolijoki, J. Sundvall, S. Keinänen-Kiukaanniemi, M. Peltonen, J. Tuomilehto, M. Uusitupa, P. Mäntyselkä, M.J. Vanhala. (2011) Ageing and associations of fasting plasma glucose and 2h plasma glucose with HbA1C in apparently healthy population. “FIN-D2D” study. Diabetes Research and Clinical Practice
CrossRef54
P. RaviKumar, A. Bhansali, R. Walia, G. Shanmugasundar, M. Ravikiran. (2011) Alterations in HbA1c with advancing age in subjects with normal glucose tolerance: Chandigarh Urban Diabetes Study (CUDS). Diabetic Medicine 28:5, 590-594
CrossRef55
Ben F. Hurley, Erik D. Hanson, Andrew K. Sheaff. (2011) Strength Training as a Countermeasure to Aging Muscle and Chronic Disease. Sports Medicine 41:4, 289-306
CrossRef56
Meredith E. Pugh, Ivan M. Robbins, Todd W. Rice, James West, John H. Newman, Anna R. Hemnes. (2011) Unrecognized glucose intolerance is common in pulmonary arterial hypertension. The Journal of Heart and Lung Transplantation
CrossRef57
The ACCORD Study Group. (2011) Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. New England Journal of Medicine 364:9, 818-828
Full Text58
Martin Buysschaert, Michael Bergman. (2011) Definition of Prediabetes. Medical Clinics of North America 95:2, 289-297
CrossRef59
J.J. Criado-Álvarez, J.C. Méndez-Cabeza Fuentes, F. Bustos Guadaño. (2011) ¿Controlamos correctamente la diabetes desde atención primaria en Talavera de la Reina (Toledo)?. SEMERGEN - Medicina de Familia 37:3, 113-118
CrossRef60
Stephen Colagiuri. (2011) Epidemiology of Prediabetes. Medical Clinics of North America 95:2, 299-307
CrossRef61
Sofiya Milman, Jill P. Crandall. (2011) Mechanisms of Vascular Complications in Prediabetes. Medical Clinics of North America 95:2, 309-325
CrossRef62
Mohsen Janghorbani, Masoud Amini. (2011) Incidence of type 2 diabetes by HbA1c and OGTT: the Isfahan Diabetes Prevention Study. Acta Diabetologica
CrossRef63
Salo Haratz, David Tanne. (2011) Diabetes, hyperglycemia and the management of cerebrovascular disease. Current Opinion in Neurology 24:1, 81-88
CrossRef64
Lawrence S.C. Law, Annette W.K. Tso, Sidney Tam, Nelson M.S. Wat, Bernard M.Y. Cheung, Karen S.L. Lam. (2011) Haemoglobin A1c is superior to fasting glucose in predicting the incidence of diabetes over 8 years among Chinese. Diabetes Research and Clinical Practice 91:2, e53-e56
CrossRef65
M. Perez, L. Gonzáles, R. Olarte, N.I. Rodríguez, M. Tabares, J.P. Salazar, S. Jaimes, R.G. García, P. López-Jaramillo. (2011) Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population. Preventive Medicine 52:2, 174-177
CrossRef66
G. Schernthaner. (2011) Kidney disease in diabetology: lessons from 2010. Nephrology Dialysis Transplantation 26:2, 454-457
CrossRef67
Ronald T. Ackermann, Yiling J. Cheng, David F. Williamson, Edward W. Gregg. (2011) Identifying Adults at High Risk for Diabetes and Cardiovascular Disease Using Hemoglobin A1c. American Journal of Preventive Medicine 40:1, 11-17
CrossRef68
Joan I.A. Campbell-Tofte, Per Mølgaard, Knud Josefsen, Zostam Abdallah, Steen Honoré Hansen, Claus Cornett, Huiling Mu, Erik A. Richter, Henning Willads Petersen, Jens Christian Nørregaard, Kaj Winther. (2011) Randomized and double-blinded pilot clinical study of the safety and anti-diabetic efficacy of the Rauvolfia-Citrus tea, as used in Nigerian Traditional Medicine. Journal of Ethnopharmacology 133:2, 402-411
CrossRef69
Hyung Geun Oh, Eun-Jung Rhee, Tae-Woong Kim, Kyung Bok Lee, Jeong-Ho Park, Kwang-Ik Yang, Dushin Jeong, Hyung-Kook Park. (2011) Higher Glycated Hemoglobin Level Is Associated with Increased Risk for Ischemic Stroke in Non-Diabetic Korean Male Adults. Diabetes & Metabolism Journal 35:5, 551
CrossRef70
Elizabeth Selvin, Frederick L. Brancati. (2011) A conundrum addressed: the prognostic value of HbA1c. Nature Reviews Endocrinology 7:1,
CrossRef71
Yao Liu, Yan-min Yang, Jun Zhu, Hui-qiong Tan, Yan Liang, Jian-dong Li. (2011) Prognostic significance of hemoglobin A1c level in patients hospitalized with coronary artery disease. A systematic review and meta-analysis. Cardiovascular Diabetology 10:1, 98
CrossRef72
Samiul A Mostafa, Kamlesh Khunti, Balasubramanian Thiagarajan Srinivasan, David Webb, Melanie J Davies. (2011) Detecting Type 2 diabetes and impaired glucose regulation using glycated hemoglobin in different populations. Diabetes Management 1:1, 77-97
CrossRef73
Kazuyo Nakamura, Hinako Nanri, Megumi Hara, Yasuki Higaki, Takeshi Imaizumi, Naoto Taguchi, Tatsuhiko Sakamoto, Mikako Horita, Koichi Shinchi, Keitaro Tanaka. (2011) Optimal cutoff values of waist circumference and the discriminatory performance of other anthropometric indices to detect the clustering of cardiovascular risk factors for metabolic syndrome in Japanese men and women. Environmental Health and Preventive Medicine 16:1, 52-60
CrossRef74
D. Preiss, K. Khunti, N. Sattar. (2011) Combined cardiovascular and diabetes risk assessment in primary care. Diabetic Medicine 28:1, 19-22
CrossRef75
G. Cavagnolli, J. Comerlato, C. Comerlato, P. B. Renz, J. L. Gross, J. L. Camargo. (2011) HbA1c measurement for the diagnosis of diabetes: is it enough?. Diabetic Medicine 28:1, 31-35
CrossRef76
Michelle Greiver, Babak Aliarzadeh, Rahim Moineddin, Christopher Meaney, Noah Ivers. (2011) Diabetes screening with hemoglobin A1c prior to a change in guideline recommendations: prevalence and patient characteristics. BMC Family Practice 12:1, 91
CrossRef77
A. S. Wierzbicki. (2011) Cardiovascular screening: which populations, what measures of risk?. International Journal of Clinical Practice 65:1, 3-5
CrossRef78
M.G. Hennerici. (2011) Report of the 20th European Stroke Conference, Hamburg, May 24–27, 2011. Cerebrovascular Diseases 32:6, 589-613
CrossRef79
H. C. Gerstein, S. Islam, S. Anand, W. Almahmeed, A. Damasceno, A. Dans, C. C. Lang, M. A. Luna, M. McQueen, S. Rangarajan, A. Rosengren, X. Wang, S. Yusuf. (2010) Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia 53:12, 2509-2517
CrossRef80
Robert P. Giugliano, Eugene Braunwald. (2010) The Year in Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology 56:25, 2126-2138
CrossRef81
Philip Greenland, Joseph S. Alpert, George A. Beller, Emelia J. Benjamin, Matthew J. Budoff, Zahi A. Fayad, Elyse Foster, Mark A. Hlatky, John McB. Hodgson, Frederick G. Kushner, Michael S. Lauer, Leslee J. Shaw, Sidney C. Smith, Allen J. Taylor, William S. Weintraub, Nanette K. Wenger. (2010) 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Journal of the American College of Cardiology 56:25, e50-e103
CrossRef82
Bruce Ovbiagele. (2010) SWEET-FIX. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:4, 185-191
CrossRef83
Philip Greenland, Joseph S. Alpert, George A. Beller, Emelia J. Benjamin, Matthew J. Budoff, Zahi A. Fayad, Elyse Foster, Mark A. Hlatky, John McB. Hodgson, Frederick G. Kushner, Michael S. Lauer, Leslee J. Shaw, Sidney C. Smith, Allen J. Taylor, William S. Weintraub, Nanette K. Wenger. (2010) 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary. Journal of the American College of Cardiology 56:25, 2182-2199
CrossRef84
D. Preiss, N. Sattar. (2010) HbA1c: a useful cardiovascular risk marker in those without diabetes?. Diabetologia 53:12, 2468-2469
CrossRef85
Yutaka Seino, Kishio Nanjo, Naoko Tajima, Takashi Kadowaki, Atsunori Kashiwagi, Eiichi Araki, Chikako Ito, Nobuya Inagaki, Yasuhiko Iwamoto, Masato Kasuga, Toshiaki Hanafusa, Masakazu Haneda, Kohjiro Ueki. (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetology International 1:1, 2-20
CrossRef86
Federica Braga, Alberto Dolci, Andrea Mosca, Mauro Panteghini. (2010) Biological variability of glycated hemoglobin. Clinica Chimica Acta 411:21-22, 1606-1610
CrossRef87
Alethea N. Hill, Susan J. Appel. (2010) Diagnosing Diabetes with A1C. The Nurse Practitioner 35:10, 16-23
CrossRef88
, Yutaka Seino, Kishio Nanjo, Naoko Tajima, Takashi Kadowaki, Atsunori Kashiwagi, Eiichi Araki, Chikako Ito, Nobuya Inagaki, Yasuhiko Iwamoto, Masato Kasuga, Toshiaki Hanafusa, Masakazu Haneda, Kohjiro Ueki. (2010) Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Journal of Diabetes Investigation 1:5, 212-228
CrossRef89
ES Kilpatrick, PH Winocour. (2010) ABCD position statement on haemoglobin A1c for the diagnosis of diabetes. Practical Diabetes International 27:7, 306-310
CrossRef90
Helen L. Lutgers, Reindert Graaff, Rindert De Vries, Andries J. Smit, Robin P. F. Dullaart. (2010) Carotid artery intima media thickness associates with skin autofluoresence in non-diabetic subjects without clinically manifest cardiovascular disease. European Journal of Clinical Investigation 40:9, 812-817
CrossRef91
Jesse Foote, Jennifer Giuseffi, Medha N. Munshi. (2010) Diabetes in the Elderly. Current Cardiovascular Risk Reports 4:5, 347-353
CrossRef92
Erwin D Schleicher. (2010) A race for RAGE ligands. Kidney International 78:3, 234-236
CrossRef93
2010. Public Health Aspects of Diabetes. , 16-21.
CrossRef94
Nicholas J. Wareham, Roman Pfister. (2010) Diabetes: Glycated hemoglobin is a marker of diabetes and CVD risk. Nature Reviews Cardiology 7:7, 367-368
CrossRef95
Shamsa Ali, Vivian A. Fonseca. (2010) Diabetes: Low HbA1c levels and mortality in type 2 diabetes mellitus. Nature Reviews Endocrinology 6:7, 359-360
CrossRef96
Linda Koch. (2010) Diabetes: Prognostic validity of HbA1c levels in nondiabetic adults. Nature Reviews Endocrinology 6:6, 296-296
CrossRef97
(2010) Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults. New England Journal of Medicine 362:21, 2030-2031
Full Text98
Francisco J. Gomez-Perez, Carlos A. Aguilar-Salinas, Paloma Almeda-Valdes, Daniel Cuevas-Ramos, Israel Lerman Garber, Juan A. Rull. (2010) HbA1c for the Diagnosis of Diabetes Mellitus in a Developing Country. A Position Article. Archives of Medical Research 41:4, 302-308
CrossRef99
Cristina Bianchi, Giuseppe Penno, Roberto Miccoli, Stefano Prato. (2010) Blood Glucose Control and Coronary Heart Disease. Herz 35:3, 148-159
CrossRef100
Woo-Jun Yun. (2010) Relationship between Glycemic Control and Diabetic Retinopathy. Journal of the Korean Geriatrics Society 14:4, 234
CrossRef
- Letters
